Paid Clinical Trials Montreal

Discover 1,098 paid clinical trials in Montreal, Quebec. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,098

Observational StudyPancreatic Cancer Early Detection Consortium

Recruiting

Sponsor:

Arbor Research Collaborative for Health

Location:

Montreal, Worcester MA, Boston MA, Rochester NYshow 34 more

Code:

NCT04970056

Conditions

Pancreas Cancer

Pancreas Cyst

Pancreatic Ductal Adenocarcinoma

Genetic Predisposition

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

BMS-986340, Nivolumab, DocetaxelA Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Recruiting

PHASE1

PHASE2

Sponsor:

Bristol-Myers Squibb

Location:

Montreal, Ottawa, Hackensack NJ, New York NYshow 10 more

Code:

NCT04895709

Conditions

Cervical Cancer

Gastric/Gastroesophageal Junction Adenocarcinoma

Microsatellite Stable Colorectal Cancer

Non-Small-Cell Lung Cancer

Squamous Cell Carcinoma of Head and Neck

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BMS-986340

BMS-936558-01

Docetaxel

LymfitLymfit to Improve the Fitness and Quality of Life in Lymphoma Survivors

Recruiting

Sponsor:

McGill University

Location:

Montreal

Code:

NCT05257785

Conditions

Lymphoma

Cancer Survivors

Eligibility Criteria

Sex: All

Age: 18 - 39

Healthy Volunteers: Not accepted

Interventions

Lymfit exercise intervention

Waitlist control

CanagliflozinSafety and Efficacy of Canagliflozin in Advanced CKD

Recruiting

Sponsor:

McGill University Health Centre/Research Institute of the McGill University Health Centre

Location:

Montreal

Code:

NCT05309785

Conditions

ESRD

CKD Stage 4

CKD Stage 5

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Invokana 300 mg and 100 mg tablet

Observational StudyEarly-life MRI Biomarkers of Longer-term Respiratory Morbidity in Infants Born Extremely Preterm (EMBLEM)

Recruiting

Sponsor:

Children's Hospital of Eastern Ontario

Location:

Montreal, Ottawa, Toronto

Code:

NCT06065215

Conditions

Lung Function

BPD - Bronchopulmonary Dysplasia

Eligibility Criteria

Sex: All

Age: 35 - 21

Healthy Volunteers: Not accepted

Interventions

Magnetic Resonance Imaging (MRI)

Echocardiogram

Lung ultrasound

Observational StudyImproving Performance in Pediatric Trauma by Teaching Nontechnical Skills

Recruiting

Sponsor:

McGill University Health Centre/Research Institute of the McGill University Health Centre

Location:

Montreal

Code:

NCT05910515

Conditions

Injuries

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Debriefing

IDE196 & CrizotinibIDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Recruiting

PHASE2

PHASE3

Sponsor:

IDEAYA Biosciences

Location:

Montreal, Boston MA, Buffalo NY, Manhasset NYshow 24 more

Code:

NCT05987332

Conditions

Metastatic Uveal Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IDE196

Crizotinib

Pembrolizumab

Ipilimumab

Nivolumab

Physiotherapy ModelImpacts of an Advanced Practice Physiotherapy Model of Care for Adults With a Peripheral Musculoskeletal Disorders Referred to an Orthropaedic Outpatient Clinic

Recruiting

Sponsor:

Ciusss de L'Est de l'Île de Montréal

Location:

Montreal

Code:

NCT05714332

Conditions

Musculoskeletal Disorders

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Advanced practice physiotherapy and orthopedic surgeon management

Orthopedic surgeon management

Sunitinib, Temozolomide, RadiationCombining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

Recruiting

PHASE2

Sponsor:

Bassam Abdulkarim

Location:

Montreal, Calgary

Code:

NCT02928575

Conditions

Glioblastoma Multiforme

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Sunitinib

Temozolomide

Radiation Therapy

Rilvegostomig & Fluoropyrimidine & Trastuzumab DeruxtecanA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Montreal

Code:

NCT06764875

Conditions

HER2-positive Gastric Cancer

Gastroesophageal Junction Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Rilvegostomig

Trastuzumab deruxtecan

Trastuzumab

Pembrolizumab

5-fluorouracil

Paid Clinical Trials Montreal

Filter results

Observational StudyPancreatic Cancer Early Detection Consortium

BMS-986340, Nivolumab, DocetaxelA Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

LymfitLymfit to Improve the Fitness and Quality of Life in Lymphoma Survivors

CanagliflozinSafety and Efficacy of Canagliflozin in Advanced CKD

Observational StudyEarly-life MRI Biomarkers of Longer-term Respiratory Morbidity in Infants Born Extremely Preterm (EMBLEM)

Interested in new trials?

Observational StudyImproving Performance in Pediatric Trauma by Teaching Nontechnical Skills

IDE196 & CrizotinibIDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

Physiotherapy ModelImpacts of an Advanced Practice Physiotherapy Model of Care for Adults With a Peripheral Musculoskeletal Disorders Referred to an Orthropaedic Outpatient Clinic

Sunitinib, Temozolomide, RadiationCombining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

Rilvegostomig & Fluoropyrimidine & Trastuzumab DeruxtecanA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer